ArticleThe American journal of pathology2002
Suppression of diabetic retinopathy with angiopoietin-1.
Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 201 citations in OpenAlex.
- Analysis of cytokines in the aqueous humor during intravitreal Ranibizumab treatment of diabetic macular edema.Scientific reports · 2021Trial
- Integrative transcriptomic and machine learning analysis identifies key extracellular matrix-related genes in diabetic retinopathy.Scientific reports · 2026Article
- Inflammatory Biomarkers in Diabetic Macular Edema.Journal of clinical medicine · 2026Review
- Beyond VEGF: Angiopoietin-Tie Signaling Pathway in Diabetic Retinopathy.Journal of clinical medicine · 2024Review
- Diabetic retinopathy: emerging concepts of current and potential therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Hyperglycemia and prematurity: a narrative review.Pediatric research · 2023Review
- Polymorphisms inArchives of endocrinology and metabolism · 2023Article
- Increased Angiopoietin-1 and -2 levels in human vitreous are associated with proliferative diabetic retinopathy.PloS one · 2023Article
- C-terminal binding protein 2 promotes high-glucose-triggered cell proliferation, angiogenesis and cellular adhesion of human retinal endothelial cell line.International ophthalmology · 2022Article
- Recent Advancements in the Medical Treatment of Diabetic Retinal Disease.International journal of molecular sciences · 2021Review
- Angiopoietin 1 release from human neutrophils is independent from neutrophil extracellular traps (NETs).BMC immunology · 2021Article
- Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data.Eye (London, England) · 2021Review
- Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade.Eye (London, England) · 2020Review
- Luo Tong Formula Alleviates Diabetic Retinopathy in Rats Through Micro-200b Target.Frontiers in pharmacology · 2020Article
- Intravitreal AAV2.COMP-Ang1 Attenuates Deep Capillary Plexus Expansion in the Aged Diabetic Mouse Retina.Investigative ophthalmology & visual science · 2019Article
- Targeting VE-PTP phosphatase protects the kidney from diabetic injury.The Journal of experimental medicine · 2019Article
- Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential.Journal of diabetes research · 2019Review
- Sweet Stress: Coping With Vascular Dysfunction in Diabetic Retinopathy.Frontiers in physiology · 2018Review
- Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis.Biomolecules · 2017Review
- Role of Angiopoietins and Tie-2 in Diabetic Retinopathy.Electronic physician · 2017Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Diabetic retinopathy remains a leading cause of irreversible blindness. A critical early pathology in the disease is the adhesion of leukocytes to the retinal vasculature, a process that occurs, in part, via intercellular adhesion molecule-1. Once leukocyte adhesion occurs, endothelial cell injury ensues, as does blood-retinal barrier breakdown. Here we show that angiopoietin-1 can prevent and reverse these diabetic retinal vascular changes in both new and established diabetes. Angiopoietin-1, when given intravitreally to newly diabetic rats, normalized retinal vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1 mRNA and protein levels, leading to reductions in leukocyte adhesion, endothelial cell injury, and blood-retinal barrier breakdown. When an adenovirus coding for angiopoietin-1 was given systemically to mice with established diabetes, it similarly inhibited leukocyte adhesion and endothelial cell injury and blood-retinal barrier breakdown. These changes coincided with reductions in retinal eNOS, nitric oxide, Akt (protein kinase B), and MAP kinase activity, known mediators of VEGF bioactivity and leukocyte adhesion. When endogenous VEGF bioactivity was inhibited with a soluble Flt-1/Fc chimera, retinal Akt kinase activity was significantly reduced in vivo. Taken together, these data document new vascular and anti-inflammatory bioactivities for angiopoietin-1 and identify it as the first naturally occurring protein that directly protects the retinal vasculature in diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.